Sanofi's Diabetes Sales Force Increase Not Due To Threat From Exubera Or Levemir, Exec Says
This article was originally published in The Pink Sheet Daily
Sanofi attributes its increased detailing focus on the diabetes market to changing prescribing trends, not increased competition.
You may also be interested in...
Planned second quarter launch would be nearly one year after FDA approval.
Pfizer's Exubera is the first inhaled insulin to clear FDA; labeling recommends lung function testing.
The firm acquires Sanofi-Aventis’ rights to the inhaled insulin product through a change-in-control clause.